Sage Journals: Discover world-class research

Abstract

This scoping review examines factors influencing attitude, knowledge, decision-making, and cannabis use in people with multiple sclerosis (PwMS). We searched PubMed, CINAHL (EBSCO), PsycINFO (ProQuest), and Scopus on June 9, 2024, and registered the protocol on the Open Science Framework (DOI:10.17605/OSF.IO/SMFZ5). Quantitative, qualitative, and empirical peer-reviewed articles on cannabis use prevalence, perception, knowledge, attitude, decision-making, and influencing factors by PwMS were included, whereas overviews, commentaries, reviews, book chapters, or dissertations were excluded. We retrieved 345 articles, screened 116 for eligibility, and found 13 qualified. Cannabis use in PwMS was associated with gender, age, smoking experience, education, employment, disability magnitude, and legalization status. Reported incentives included pain relief, sleep improvement, and spasticity reduction. Family, friends, health care providers, and state laws influenced decisions to use cannabis. Inhibitors included legal issues, lack of information, health risks, side effects, parental disapproval, religious views, and costs of cannabis products. As cannabis legalization expands, understanding its use patterns and impacts among PwMS is crucial, particularly for usage duration, frequency, and interaction with multiple medications and therapies. We proposed a cannabis use framework to help health care providers assess the intention, interest, status, and experience in cannabis use/disuse of PwMS.

Keywords

cannabis use cannabis attitude multiple sclerosis decision-making

Get full access to this article

View all access options for this article.

References

Abrams

D. I.

(2018). The therapeutic effects of cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine, 49, 7–11. https://doi.org/10.1016/j.ejim.2018.01.003

Amato

Minozzi

Mitrova

Parmelli

Saulle

Cruciani

Vecchi

Davoli

(2017). Revisione sistematica sull’efficacia terapeutica e la sicurezza della cannabis per i pazienti affetti da sclerosi multipla, dolore neuropatico cronico e pazienti oncologici che assumono chemioterapie [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy]. Epidemiologia & Prevenzione, 41(5–6), 279–293. https://doi.org/10.19191/ep17.5-6.Ad01.069

Banwell

Pavisian

Lee

Feinstein

(2016). Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis. Multiple Sclerosis and Related Disorders, 10, 123–126. https://doi.org/10.1016/j.msard.2016.09.008

Bebo

Cintina

LaRocca

Ritter

Talente

Hartung

Ngorsuraches

Wallin

Yang

(2022). The economic burden of multiple sclerosis in the United States. Neurology, 98(18), e1810–e1817. https://doi.org/10.1212/WNL.0000000000200150

Benedict

R. H. B.

Amato

M. P.

DeLuca

Geurts

J. J. G.

(2020). Cognitive impairment in multiple sclerosis: Clinical management, MRI, and therapeutic avenues. Lancet Neurol, 19(10), 860–871. https://doi.org/10.1016/s1474-4422(20)30277-5

Boehnke

K. F.

Litinas

Worthing

Conine

Kruger

D. J.

(2021). Communication between healthcare providers and medical cannabis patients regarding referral and medication substitution. Journal of Cannabis Research, 3(1), 2. https://doi.org/10.1186/s42238-021-00058-0

Boggs

D. L.

Peckham

Boggs

A. A.

Ranganathan

(2016). Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion. Ment Health Clin, 6(6), 277–284. https://doi.org/10.9740/mhc.2016.11.277

Braley

T. J.

Whibley

Alschuler

K. N.

Ehde

D. M.

Chervin

R. D.

Clauw

D. J.

Williams

Kratz

A. L.

(2020). Cannabinoid use among Americans with MS: Current trends and gaps in knowledge. Multiple Sclerosis Journal—Experimental, Translational and Clinical, 6(3), 2055217320959816. https://doi.org/10.1177/2055217320959816

Brenton

J. N.

Schreiner

Karoscik

Richter

Ferrante

Waldman

Banwell

(2018). Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis. Journal of Neurology, 265(2), 417–423. https://doi.org/10.1007/s00415-017-8715-5

10.

Centers for Disease Control and Prevention. (n.d.). Current cigarette smoking among adults in the United States. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#:~:text=In%202021%2C%20nearly%2012%20of,with%20a%20smoking%2Drelated%20disease.

11.

Cofield

S. S.

Salter

Tyry

Crowe

Cutter

G. R.

Fox

R. J.

Marrie

R. A.

(2017). Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants. Neurology Clinical Practice, 7(4), 333–343. https://doi.org/10.1212/cpj.0000000000000383

12.

DeLuca

Chiaravalloti

N. D.

Sandroff

B. M.

(2020). Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nature Reviews Neurology, 16(6), 319–332. https://doi.org/10.1038/s41582-020-0355-1

13.

Drulovic

Basic-Kes

Grgic

Vojinovic

Dincic

Toncev

Kezic

M. G.

Kisic-Tepavcevic

Dujmovic

Mesaros

Miletic-Drakulic

Pekmezovic

(2015). The prevalence of pain in adults with multiple sclerosis: A multicenter cross-sectional survey. Pain Medications, 16(8), 1597–1602. https://doi.org/10.1111/pme.12731

14.

Ehde

D. M.

Alschuler

K. N.

Osborne

T. L.

Hanley

M. A.

Jensen

M. P.

Kraft

G. H.

(2015). Utilization and patients’ perceptions of the effectiveness of pain treatments in multiple sclerosis: A cross-sectional survey. Disability and Health Journal, 8(3), 452–456. https://doi.org/10.1016/j.dhjo.2015.03.001

15.

Einhorn

H. J.

Hogarth

R. M.

(1986). Decision making under ambiguity. The Journal of Business, 59(4), S225–S250. http://www.jstor.org/stable/2352758

16.

Fischhoff

(2013). Assessing adolescent decision-making competence. In Judgment and decision making (pp. 300–319). Routledge.

17.

Frisch

Clemen

R. T.

(1994). Beyond expected utility: Rethinking behavioral decision research. Psychological Bulletin, 116(1), 46–54. https://doi.org/10.1037/0033-2909.116.1.46

18.

Geva

Mintz

(1997). Decisionmaking on war and peace: The cognitive-rational debate. Lynne Rienner Publishers.

19.

Government of Canada. (2021). Cannabis legalization and regulation. https://www.justice.gc.ca/eng/cj-jp/cannabis/

20.

Government of Canada. (n.d.). Canadian Cannabis Survey 2021: Summary. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2021-summary.html

21.

Gözübatık Çelik

R. G.

Öztürk

Altın

Köseoğlu

Sariahmetoğlu

Tütüncü

Soysal

(2019). The prevalence of alternative-complementary therapies in patients with multiple sclerosis. Turkish Journal of Neurology, 25(3), 153–158. https://doi.org/10.4274/tnd.2019.04207

22.

Gupta

Fellows

Weinstock-Guttman

Hagemeier

Zivadinov

Ramanathan

(2019). Marijuana use by patients with multiple sclerosis. International Journal of MS Care, 21(2), 57–62. https://doi.org/10.7224/1537-2073.2017-112

23.

Hasin

D. S.

Saha

T. D.

Kerridge

B. T.

Goldstein

R. B.

Chou

S. P.

Zhang

Jung

Pickering

R. P.

Ruan

W. J.

Smith

S. M.

Huang

Grant

B. F.

(2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12), 1235–1242. https://doi.org/10.1001/jamapsychiatry.2015.1858

24.

Hildebrand

Minnier

Cameron

M. H.

(2020). Cannabis use for symptom relief in multiple sclerosis: A cross-sectional survey of webinar attendees in the US and Canada. Multiple Sclerosis and Related Disorders, 38, 101516. https://doi.org/10.1016/j.msard.2019.101516

25.

Hogarth

R. M.

(1987). Judgement and choice: The psychology of decision. Wiley. https://books.google.com/books?id=dN6tB3Z552gC

26.

Kister

Bacon

T. E.

Chamot

Salter

A. R.

Cutter

G. R.

Kalina

J. T.

Herbert

(2013). Natural history of multiple sclerosis symptoms. International Journal of MS Care, 15(3), 146–158. https://doi.org/10.7224/1537-2073.2012-053

27.

Kołtuniuk

Kazimierska-Zając

Pogłódek

Chojdak-Łukasiewicz

(2022). Sleep disturbances, degree of disability and the quality of life in multiple sclerosis patients. International Journal of Environmental Research and Public Health, 19(6). https://doi.org/10.3390/ijerph19063271

28.

Leblanc

Lefort

Le Page

Michel

Leray

(2022). Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France. Expert Review of Neurotherapeutics, 22(5), 411–418. https://doi.org/10.1080/14737175.2022.2061950

29.

Linassi

A. G.

Hader

W. J.

(2003). Perceived effects of marijuana use by MS patients in Saskatchewan – a pilot study. International Journal of MS Care, 5(4), 139–147. https://doi.org/10.7224/1537-2073-5.4.139

30.

Link

Knowles

L. M.

Alschuler

K. N.

Ehde

D. M.

(2023). Characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: An observational study. Multiple Sclerosis and Related Disorders, 75, 104742. https://doi.org/10.1016/j.msard.2023.104742

31.

Mak

Thomas

(2022). Steps for conducting a scoping review. Journal of Graduate Medical Education, 14(5), 565–567.

32.

Marck

C. H.

De Livera

A. M.

Weiland

T. J.

Jelinek

P. L.

Neate

S. L.

Brown

C. R.

Taylor

K. L.

Khan

Jelinek

G. A.

(2017). Pain in people with multiple sclerosis: Associations with modifiable lifestyle factors, fatigue, depression, anxiety, and mental health quality of life. Frontiers in Neurology, 8, 461. https://doi.org/10.3389/fneur.2017.00461

33.

Marck

C. H.

Neate

S. L.

Taylor

K. L.

Weiland

T. J.

Jelinek

G. A.

(2016). Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PLOS ONE, 11(2), e0148573. https://doi.org/10.1371/journal.pone.0148573

34.

National Center for Drug Abuse Statistics. (n.d.). Drug overdose death rates. https://drugabusestatistics.org/drug-overdose-deaths/

35.

National Conference of State Legislatures. (2023). State medical cannabis laws. https://www.ncsl.org/health/state-medical-cannabis-laws

36.

National Institute on Alcohol Abuse and Alcoholism. (2015). Prevalence of marijuana use among U.S. adults doubles over past decade. https://www.nih.gov/news-events/news-releases/prevalence-marijuana-use-among-us-adults-doubles-over-past-decade#:~:text=Surveys%20show%209.5%20percent%20of,time%20was%20nearly%20as%20large

37.

National Institute on Drug Abuse. (2022, December 15). Most reported substance use among adolescents held steady in 2022. https://nida.nih.gov/news-events/news-releases/2022/12/most-reported-substance-use-among-adolescents-held-steady-in-2022

38.

National Multiple Sclerosis Society. (n.d.). Cost of multiple sclerosis. https://www.nationalmssociety.org/Living-Well-With-MS/Work-and-Home/Cost-of-Multiple-Sclerosis

39.

Oliva Ramirez

Keenan

Kalau

Worthington

Cohen

Singh

(2021). Prevalence and burden of multiple sclerosis-related fatigue: A systematic literature review. BMC Neurology, 21(1), 468. https://doi.org/10.1186/s12883-021-02396-1

40.

Oliveira

(2007). A discussion of rational and psychological decision-making theories and models: The search for a cultural-ethical decision-making model. Electronic Journal of Business Ethics and Organization Studies, 12(2), 12–17.

41.

Page

S. A.

Verhoef

M. J.

Stebbins

R. A.

Metz

L. M.

Levy

J. C.

(2003). Cannabis use as described by people with multiple sclerosis. Canadian Journal of Neurological Sciences, 30(3), 201–205. https://doi.org/10.1017/s0317167100002584

42.

Rice

Hildebrand

Spain

Senders

Silbermann

Wooliscroft

Yadav

Bourdette

Cameron

(2021). A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington. Multiple Sclerosis and Related Disorders, 55, 103172. https://doi.org/10.1016/j.msard.2021.103172

43.

Schabas

A. J.

Vukojevic

Taylor

Thu

Badyal

Chan

J. K.

Devonshire

Traboulsee

Sayao

A. L.

Carruthers

(2019). Cannabis-based product use in a multiple sclerosis cohort. Multiple Sclerosis Journal—Experimental, Translational and Clinical, 5(3), 2055217319869360. https://doi.org/10.1177/2055217319869360

44.

Simmons

R. D.

Ponsonby

A. L.

van der Mei

I. A.

Sheridan

(2004). What affects your MS? Responses to an anonymous, Internet-based epidemiological survey. Multiple Sclerosis Journal, 10(2), 202–211. https://doi.org/10.1191/1352458504ms1006oa

45.

Tricco

A. C.

Lillie

Zarin

O’Brien

K. K.

Colquhoun

Levac

Moher

Peters

M. D. J.

Horsley

Weeks

Hempel

Akl

E. A.

Chang

McGowan

Stewart

Hartling

Aldcroft

Wilson

M. G.

Garritty

. . .Straus

S. E.

(2018). PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Annals of Internal Medicine, 169(7), 467–473. https://doi.org/10.7326/m18-0850

46.

Turner

McDonald

(2023). An interdisciplinary approach to misinformation and concept drift in historical cannabis tweets. In 2023 IEEE 17th International Conference on Semantic Computing (ICSC) (pp. 317–322). IEEE.

47.

U.S. Food and Drug Administration. (2023). FDA regulation of cannabis and cannabis-derived products, including Cannabidiol (CBD). https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#whatare

48.

Walton

King

Rechtman

Kaye

Leray

Marrie

R. A.

Robertson

La Rocca

Uitdehaag

van der Mei

Wallin

Helme

Angood Napier

Rijke

Baneke

(2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 26(14), 1816–1821. https://doi.org/10.1177/1352458520970841

49.

Weiner

(1985). Attribution theory. In Weiner

(Ed.), Human motivation (pp. 275–326). Springer. https://doi.org/10.1007/978-1-4612-5092-0_7

50.

Yadav

Shinto

Bourdette

(2010). Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Review of Clinical Immunology, 6(3), 381–395. https://doi.org/10.1586/eci.10.12

51.

Zenone

Snyder

Caulfield

(2020). Crowdfunding Cannabidiol (CBD) for cancer: Hype and misinformation on GoFundMe. American Journal of Public Health, 110(S3), S294–s299. https://doi.org/10.2105/ajph.2020.305768

52.

Zhang

Salter

Jin

Culpepper

W. J.

2nd Cutter

G. R.

Wallin

Stuve

(2021). Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. Therapeutic Advances in Neurological Disorders, 14, 17562864211006499. https://doi.org/10.1177/17562864211006499

Attitude and Use of Cannabis in People With Multiple Sclerosis: A Scoping Review

Abstract

Keywords

Get full access to this article

References